🇪🇺EU · EMAAuthorisedATC: J07BB03

Fluenz(influenza virus A/Victoria/4897/2022  (H1N1)pdm09 - like strain (A/Norway/31694/2022, MEDI 369815), A A/Croatia/10136RV/2023 (H3N2)-like strain (A/Perth/722/2024, MEDI 392611) B/Austria/1359417/2021 - like strain (B/ Austria/1359417/2021, MEDI 355292))

Influenza, Human

Marketing Authorisation Holder: AstraZeneca AB

EMA Authorisation: 03/06/2024

INN: influenza vaccine (live attenuated, nasal)

Indication

Fluenz is indicated for active immunisation for the prevention of influenza disease in children and adolescents from 2 years to less than 18 years of age.Fluenz should be used in accordance with official recommendations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Fluenz — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Fluenz Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.

Fluenz(influenza virus A/Victoria/4897/2022 (H1N1)pdm09 - like strain (A/Norway/31694/2022, MEDI 369815), A A/Croatia/10136RV/2023 (H3N2)-like strain (A/Perth/722/2024, MEDI 392611) B/Austria/1359417/2021 - like strain (B/ Austria/1359417/2021, MEDI 355292))

Indication

Official EMA Resources

Fluenz(influenza virus A/Victoria/4897/2022  (H1N1)pdm09 - like strain (A/Norway/31694/2022, MEDI 369815), A A/Croatia/10136RV/2023 (H3N2)-like strain (A/Perth/722/2024, MEDI 392611) B/Austria/1359417/2021 - like strain (B/ Austria/1359417/2021, MEDI 355292))